[
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.Preclinical advances\nResistance to CAR T cells is occurred due to the heterogeneity of the antigens presented by brain tumors, stressing the need for a larger library of targeted antigens.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CARs mimic the canonical T cell pathway by virtue of the inclusion of either a single-chain variable fragment (ScFv) derived from a monoclonal antibody or a mutated ligand for target binding, one or more co-stimulatory domains, and the ξ chain of the CD3 complex within a single multi-domain receptor (Fig. 1) [13].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The introduction of CAR into T cells allows them to eliminate cells expressing specific target antigen(s) through the same effector functions utilized by wild-type T cells to kill infected or transformed cells (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CAR T cells can broadly be grouped into five generations based on how their intracellular signaling domains are organized, despite the fact that their essential modular structure has not changed since their inception (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "T cells are activated by engaging their T cell receptors, and co-stimulatory receptors (mostly anti-CD3 and anti-CD28) and/or adhesion molecule(s) (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Well-characterized antigens remain the focus for designing bispecific ‘OR-gated’ CARs against brain tumors (Fig. 2a).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel a",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Regarding design considerations of bispecific CARs, the ‘tandem’ design sequentially arranges the heavy and light chains of each ScFv while the ‘loop’ pattern resembles the bivalent antibody structure (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incorporation of a third targeting domain (trispecific CARS) can further intensify this approach (Fig. 2c) [48].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Alternatively, multi-antigen targeting can be addressed by expressing two CARs on the same T cell, and/or by mixing different single-targeted CAR T cells (Fig. 2d) [50, 51].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel d",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lead tumor antigen candidates were chosen based on evidence of negligible expression in the normal brain, and the history of overexpression on malignant cells (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A schematic overview of checkpoint inhibition in combination with CAR T cell therapy has been depicted in Fig. 4a.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "An overview of the mechanistic impacts of different immunosuppressive drugs in combination with CAR T cells in the efficacious management of brain cancers has been depicted in Fig. 4b.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The mechanistic insight has been hypothesized in Fig. 4c.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel c",
        "figure_key": "figure_4"
      }
    ]
  }
]